NASDAQ:PTIE - Pain Therapeutics Stock Price, Price Target & More

$7.85 +0.15 (+1.95 %)

(As of 04/20/2018 06:00 AM ET)

Previous Close$7.85

Today's Range$7.5536 - $7.86

52-Week Range$3.10 - $12.80

Volume14,006 shs

Average Volume579,928 shs

Market Capitalization$55.10 million

P/E Ratio-4.31

Dividend YieldN/A

Beta2.58

About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.

Receive PTIE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:PTIE

CUSIP69562K10

Webwww.paintrials.com

Phone512-501-2444

Debt

Debt-to-Equity RatioN/A

Current Ratio9.43%

Quick Ratio9.43%

Price-To-Earnings

Trailing P/E Ratio-4.31

Forward P/E Ratio-4.76

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book Value$1.47 per share

Price / Book5.34

Profitability

EPS (Most Recent Fiscal Year)($1.82)

Net Income$-11,910,000.00

Net MarginsN/A

Return on Equity-93.35%

Return on Assets-86.53%

Miscellaneous

Employees9

Outstanding Shares6,900,000

How to Become a New Pot Stock Millionaire

Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Shares of Pain Therapeutics reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics, Inc (NASDAQ:PTIE) posted its quarterly earnings results on Monday, February, 5th. The biopharmaceutical company reported ($0.37) EPS for the quarter. View Pain Therapeutics' Earnings History.

When is Pain Therapeutics' next earnings date?

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Pain Therapeutics.

Who are some of Pain Therapeutics' key competitors?

Some companies that are related to Pain Therapeutics include Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX), Conatus Pharmaceuticals (CNAT), Alpine Immune Sciences (ALPN), Oramed Pharmaceuticals (ORMP), Forward Pharma (FWP), RedHill Biopharma (RDHL), KalVista Pharmaceuticals (KALV), Columbia Laboratories (JNP), Aileron Therapeutics (ALRN), Flex Pharma (FLKS), Agile Therapeutics (AGRX), Trillium Therapeutics (TRIL), Sunesis Pharmaceuticals (SNSS), Ophthotech (OPHT), Aralez Pharmaceuticals (ARLZ), KemPharm (KMPH) and Galmed Pharmaceuticals (GLMD).

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:

Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)
Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)
Mr. Michael J. O'Donnell, Sec. & Director (Age 60)
Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

Has Pain Therapeutics been receiving favorable news coverage?

Press coverage about PTIE stock has trended somewhat negative this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pain Therapeutics earned a news impact score of -0.06 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Pain Therapeutics?

Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of PTIE stock can currently be purchased for approximately $7.85.

How big of a company is Pain Therapeutics?

Pain Therapeutics has a market capitalization of $55.10 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.

How can I contact Pain Therapeutics?

Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444.

MarketBeat Community Rating for Pain Therapeutics (PTIE)

Community Ranking:		1.9 out of 5 ()
Outperform Votes:		80 (Vote Outperform)
Underperform Votes:		126 (Vote Underperform)
Total Votes:		206

MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Pain Therapeutics (NASDAQ:PTIE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Pain Therapeutics in the last 12 months. There are currently 1 sell rating for the stock, resulting in a consensus rating of "Sell."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Sell	Sell	Sell	Sell
Consensus Rating Score:	1.00	1.00	1.00	1.00
Ratings Breakdown:	1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Pain Therapeutics (NASDAQ:PTIE) Consensus Price Target History

Price Target History for Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics (NASDAQ:PTIE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
7/17/2017	Gabelli	Downgrade	Hold -> Sell		Low

(Data available from 4/20/2016 forward)

Pain Therapeutics (NASDAQ:PTIE) Earnings History and Estimates Chart

Earnings by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics (NASDAQ:PTIE) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.65 EPS
Next Year EPS Consensus Estimate: $-4.85 EPS

Pain Therapeutics (NASDAQ PTIE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/24/2018
2/5/2018	Q4 2017		($0.37)			View	N/A
11/1/2017	Q3 2017		($0.40)			View	N/A
8/9/2017	Q2 2017	($0.47)	($0.64)			View	N/A
4/25/2017	Q1 2017	($0.42)	($0.42)			View	N/A
2/17/2017	Q4 2016		($0.42)			View	N/A
10/20/2016	Q316	($0.63)	($0.56)			View	N/A
7/19/2016	Q216	($0.98)	($0.49)			View	N/A
5/5/2016	Q1	($0.70)	($0.91)			View	N/A
3/1/2016	Q4 2015		($0.70)			View	N/A
11/9/2015	Q3 2015		($0.56)			View	N/A
7/23/2015	Q2 2015		($0.49)			View	N/A
5/7/2015	Q1 2015		($0.42)			View	N/A
2/17/2015	Q4 2014		($0.35)			View	N/A
10/30/2014	Q314		($0.56)	$89.70 million		View	N/A
8/5/2014	Q214		($0.49)			View	N/A
5/6/2014	Q1 14	($0.42)	($0.56)	$1.96 million		View	N/A
2/4/2014	Q413	($0.07)	$5.04	$2.00 million	$35.24 million	View	N/A
10/31/2013	Q313	($0.07)	($0.14)	$2.00 million	$1.96 million	View	N/A
8/1/2013	Q2 2013	($0.07)	($0.07)		$1.96 million	View	N/A
4/24/2013	Q1 2013	($0.07)	($0.07)	$2.80 million	$1.96 million	View	N/A
2/6/2013	Q4 2012	($0.14)	($0.56)	$2.79 million	$2.47 million	View	N/A
11/8/2012	Q3 2012	($0.07)	($0.21)			View	N/A
8/2/2012	Q2 2012		($0.02)			View	N/A
5/8/2012	Q1 2012	($0.07)	$0.01			View	N/A
2/9/2012	Q4 2011	($0.14)	($0.06)			View	N/A
11/3/2011	Q3 2011	($0.14)	($0.13)			View	N/A
8/4/2011	Q2 2011	($0.14)	($0.19)			View	N/A
2/3/2011	Q4 2010		($1.50)			View	N/A
10/28/2010	Q3 2010	$0.49	($0.17)			View	N/A
7/28/2010	Q2 2010	($0.21)	($0.14)			View	N/A
4/28/2010	Q1 2010		($0.17)			View	N/A
1/28/2010	Q4 2009	($0.28)	($0.05)			View	N/A
10/29/2009	Q3 2009	($0.49)	($0.22)			View	N/A
8/4/2009	Q2 2009	($0.28)	($0.01)			View	N/A
4/30/2009	Q1 2009	($0.14)	($0.30)			View	N/A
2/5/2009	Q4 2008	$0.28	($0.22)			View	N/A
10/29/2008	Q3 2008	$2.10	$2.47			View	N/A
7/30/2008	Q2 2008	$0.70	($0.17)			View	N/A
5/7/2008	Q1 2008	$0.42	$0.40			View	N/A
2/7/2008	Q4 2007	$0.21	$0.17			View	N/A

(Earnings results data provided by Zacks Investment Research)

Pain Therapeutics (NASDAQ:PTIE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
12/11/2012	special	$5.25		12/13/2012	12/17/2012	12/24/2012

(Data available from 1/1/2013 forward)

Pain Therapeutics (NASDAQ PTIE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.40%
Institutional Ownership Percentage: 33.78%

Insider Trading History for Pain Therapeutics (NASDAQ:PTIE)

Institutional Ownership by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics (NASDAQ PTIE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/6/2013	Sanford Robertson	Director	Buy	50,000	$3.73	$186,500.00	369,727

(Data available from 1/1/2013 forward)

Pain Therapeutics (NASDAQ PTIE) News Headlines

Source:

Date	Headline
	Pain Therapeutics (PTIE) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 18 at 11:44 AM
	Gabelli Downgrades Pain Therapeutics (PTIE) to Sell www.americanbankingnews.com - April 17 at 11:28 PM
	Pain Therapeutics (PTIE) Shares March Higher, Can It Continue? finance.yahoo.com - April 12 at 5:44 PM
	Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the ... www.prnewswire.com - April 6 at 8:03 AM
	Pain Therapeutics (PTIE) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - April 3 at 9:18 PM
	Post-Operative Pain Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years: P&S ... globenewswire.com - March 31 at 5:40 PM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches ... - PR Newswire (press release) www.prnewswire.com - March 21 at 8:06 AM
	Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER® - GlobeNewswire (press release) globenewswire.com - March 20 at 8:02 AM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors www.prnewswire.com - March 19 at 7:49 AM
	Pain Therapeutics (PTIE) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - March 14 at 6:48 AM
	Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors finance.yahoo.com - March 6 at 5:32 PM
	Pain Therapeutics (PTIE) Downgraded by ValuEngine www.americanbankingnews.com - March 4 at 11:38 AM
	Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date - StreetInsider.com www.streetinsider.com - March 3 at 5:36 PM
	Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date www.streetinsider.com - March 2 at 8:23 AM
	How Should You Think About Pain Therapeutics Inc’s (NASDAQ:PTIE) Risks? finance.yahoo.com - March 1 at 5:46 PM
	FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018 finance.yahoo.com - March 1 at 8:30 AM
	Pain Therapeutics (PTIE) Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - February 24 at 4:30 PM
	Pain Therapeutics (PTIE) Upgraded at Zacks Investment Research www.americanbankingnews.com - February 22 at 9:56 AM
	Gabelli Weighs in on Pain Therapeutics, Inc.'s FY2018 Earnings (PTIE) www.americanbankingnews.com - February 16 at 11:18 AM
	Gabelli Comments on Pain Therapeutics, Inc.'s FY2022 Earnings (PTIE) www.americanbankingnews.com - February 15 at 4:28 PM
	TTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again - Nasdaq www.nasdaq.com - February 14 at 3:34 PM
	Pain Therapeutics (PTIE) Resubmits NDA for REMOXY ER - StreetInsider.com www.streetinsider.com - February 14 at 7:38 AM
	Pain Therapeutics Resubmits New Drug Application for REMOXY® ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain finance.yahoo.com - February 13 at 3:30 PM
	Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3% seekingalpha.com - February 13 at 9:57 AM
	Pain Therapeutics (PTIE) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - February 8 at 1:24 AM
	Pain Therapeutics Reports 2017 Financial Results and Corporate Update - GlobeNewswire (press release) globenewswire.com - February 6 at 7:22 AM
	Pain Therapeutics Reports 2017 Financial Results and Corporate Update finance.yahoo.com - February 5 at 3:29 PM
	Quotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics, and uniQure www.bizjournals.com - January 19 at 11:38 AM
	Gabelli Analysts Raise Earnings Estimates for Pain Therapeutics, Inc. (PTIE) www.americanbankingnews.com - January 12 at 6:54 AM
	Zacks: Pain Therapeutics, Inc. (PTIE) Given Average Rating of "Strong Sell" by Brokerages www.americanbankingnews.com - January 10 at 5:30 PM
	Earnings Growth Hamper Pain Therapeutics (PTIE) Rating investorplace.com - January 10 at 11:18 AM
	PTIE Skyrockets On Remoxy Data, ASND On An Ascent, There Is HOPE For GBT www.finanznachrichten.de - January 10 at 10:17 AM
	Does Pain Therapeutics Inc’s (NASDAQ:PTIE) Earnings Growth Make It An Outperformer? finance.yahoo.com - January 10 at 10:17 AM
	Pain Therapeutics, REMOXY Gets Positive Study Results, Updates for FENROCK and PTI-125 finance.yahoo.com - January 10 at 10:17 AM
	Here’s What’s Moving Axsome Therapeutics and Pain Therapeutics finance.yahoo.com - January 10 at 10:17 AM
	2 Biotech Stocks Climbing on Positive Findings - Baystreet.ca www.baystreet.ca - January 9 at 4:46 PM
	Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet - Benzinga www.benzinga.com - January 9 at 4:46 PM
	Pain Therapeutics Shares Double On Clinical Study Data - Benzinga www.benzinga.com - January 9 at 4:46 PM
	2 Biotech Stocks Climbing on Positive Findings finance.yahoo.com - January 9 at 4:46 PM
	Why Pain Therapeutics, Inc. (PTIE) Shares Skyrocketed 150% Today finance.yahoo.com - January 9 at 4:46 PM
	Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT) finance.yahoo.com - January 9 at 4:46 PM
	Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet feeds.benzinga.com - January 9 at 3:31 PM
	Durect up 11% on Pain Therapeutics' Remoxy-stoked rally seekingalpha.com - January 9 at 12:56 PM
	Pain Therapeutics Shares Double On Clinical Study Data feeds.benzinga.com - January 9 at 12:32 PM
	Pain Therapeutics Reports Positive Top-line Results from Nasal Abuse Potential Study with REMOXY™ finance.yahoo.com - January 9 at 10:07 AM
	Pain Therapeutics (PTIE) versus Its Peers Head-To-Head Review www.americanbankingnews.com - December 28 at 12:16 AM
	Zacks Investment Research Lowers Pain Therapeutics (PTIE) to Hold www.americanbankingnews.com - December 27 at 6:24 AM
	Pain Therapeutics Reports Positive Regulatory Meeting for REMOXY™ - GlobeNewswire (press release) globenewswire.com - December 19 at 4:39 PM
	Pain Therapeutics (PTIE) Announces Positive Regulatory Meeting for REMOXY - StreetInsider.com www.streetinsider.com - December 18 at 4:40 PM
	Health Care Sector Update for 12/18/2017: ADRO,PTIE,NVIV - Nasdaq www.nasdaq.com - December 18 at 4:40 PM

Pain Therapeutics (NASDAQ:PTIE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Pain Therapeutics (NASDAQ:PTIE) Income Statement, Balance Sheet and Cash Flow Statement

Pain Therapeutics (NASDAQ PTIE) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff